| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility
|
Modlin, I.M.
|
|
|
32 |
11 |
p. 1425-1433
|
artikel
|
| 2 |
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy
|
Cortellini, A.
|
|
|
32 |
11 |
p. 1391-1399
|
artikel
|
| 3 |
Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies
|
Pommeret, F.
|
|
|
32 |
11 |
p. 1445-1447
|
artikel
|
| 4 |
Brain metastases in solid tumours: new guidelines for a new era
|
Popat, S.
|
|
|
32 |
11 |
p. 1322-1324
|
artikel
|
| 5 |
Corrigendum to “Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
|
Baudin, E.
|
|
|
32 |
11 |
p. 1453-1455
|
artikel
|
| 6 |
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours ☆
|
Le Rhun, E.
|
|
|
32 |
11 |
p. 1332-1347
|
artikel
|
| 7 |
Early-phenotype CAR-T cells for the treatment of pediatric cancers
|
Meyran, D.
|
|
|
32 |
11 |
p. 1366-1380
|
artikel
|
| 8 |
Editorial Board
|
|
|
|
32 |
11 |
p. iii
|
artikel
|
| 9 |
Fifty years of clinical and research studies for childhood renal tumors within the International Society of Pediatric Oncology (SIOP)
|
Graf, N.
|
|
|
32 |
11 |
p. 1327-1331
|
artikel
|
| 10 |
Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL
|
van Gelder, M.
|
|
|
32 |
11 |
p. 1442-1443
|
artikel
|
| 11 |
Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: the pathologists' perspective
|
Salgado, R.
|
|
|
32 |
11 |
p. 1316-1321
|
artikel
|
| 12 |
Harmful cytokines in cancer immunology and immunotherapy: biomarkers and targets?
|
Melero, I.
|
|
|
32 |
11 |
p. 1311-1313
|
artikel
|
| 13 |
Inflammation reduces the effect of nutritional therapy on clinical outcomes in cancer patients
|
Bargetzi, L.
|
|
|
32 |
11 |
p. 1451-1452
|
artikel
|
| 14 |
Large-scale prospective genome-wide association study of oxaliplatin in stage II/III colon cancer and neuropathy
|
Kanai, M.
|
|
|
32 |
11 |
p. 1434-1441
|
artikel
|
| 15 |
Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort
|
Schrodi, S.
|
|
|
32 |
11 |
p. 1410-1424
|
artikel
|
| 16 |
Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance
|
Loriot, Y.
|
|
|
32 |
11 |
p. 1381-1390
|
artikel
|
| 17 |
Precision guidelines for soft tissue and visceral sarcomas: the evidence, expert experience and ensuring optimal care for rare cancers, a 2021 update from ESMO–EURACAN–GENTURIS
|
Gladdy, R.A.
|
|
|
32 |
11 |
p. 1325-1326
|
artikel
|
| 18 |
Progressive melanoma versus tumor melanosis: is imaging enough?
|
Davidson, T.M.
|
|
|
32 |
11 |
p. 1449-1450
|
artikel
|
| 19 |
Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients
|
Heudel, P.
|
|
|
32 |
11 |
p. 1443-1444
|
artikel
|
| 20 |
Significant response of medullary thyroid cancer choroidal metastases to highly selective RET inhibitor selpercatinib: a case report
|
Matrone, A.
|
|
|
32 |
11 |
p. 1447-1449
|
artikel
|
| 21 |
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|
Gronchi, A.
|
|
|
32 |
11 |
p. 1348-1365
|
artikel
|
| 22 |
SPARC macrophages in lymphoma
|
Piris, M.A.
|
|
|
32 |
11 |
p. 1314-1315
|
artikel
|
| 23 |
SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status
|
Croci, G.A.
|
|
|
32 |
11 |
p. 1400-1409
|
artikel
|
| 24 |
Table of Contents
|
|
|
|
32 |
11 |
p. i-ii
|
artikel
|
Tijdschrift beschrijving